NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
November 5, 2025 — NeuroOne Medical Technologies receives 180-day Nasdaq extension to regain compliance with minimum $1 stock price requirement. Medical tech company developing neurological disorder treatments gets until May 2026.
November 5, 2025 — A Place At Home – North Austin wins Best of Round Rock Award for second year. Learn about their senior home care, dementia programs & veteran support services in Williamson & Travis Counties.
November 5, 2025 — Avignon's Centre for Education challenges traditional university accreditation, advocating for pluralism in recognizing informal higher education models while maintaining academic rigor and cultural responsiveness.
November 5, 2025 — SunKnowledge Inc. revolutionizes healthcare with specialized virtual medical assistant services, offering 80% cost savings and 95% efficiency improvements for medical practices nationwide.
November 5, 2025 — BioUtah announces 2025 Life Sciences Awards honoring innovators in HIV research, cancer therapy, medical devices. Summit November 12 recognizes Utah's healthcare leadership.
November 5, 2025 — Innovotech Inc. reports record Q3-2025 revenue of $1.27M with strong growth across antimicrobial research services and analytical labs. Learn about their financial performance and expansion.
November 4, 2025 — MEDICLIN reports 41.7% profit growth to EUR 48.9M and 5.1% sales increase to EUR 586.9M in first nine months of 2025. Healthcare provider confirms annual guidance.
November 4, 2025 — Soligenix strengthens financial position with $7.5M offering, extending cash runway through 2026 to advance rare disease and biodefense pipeline with multiple catalysts ahead.
November 4, 2025 — Kairos Pharma reports 86% clinical benefit in Phase 2 prostate cancer trial with ENV105. No dose-limiting toxicities observed. Read about breakthrough cancer treatment targeting CD105 resistance.
November 4, 2025 — American Lung Association report shows critically low lung cancer screening rates despite 20% of cancer deaths. Survival rates improving to 26.6% with new treatments from companies like Calidi Biotherapeutics.
November 4, 2025 — GeoVax Labs announces Q3 2025 financial results and business update, highlighting COVID-19 vaccine trials for immunocompromised patients and oncology therapies.
November 4, 2025 — American Heart Association names 5 health tech finalists developing AI, wearable, and digital solutions to combat heart disease and stroke, the world's leading causes of death.
November 4, 2025 — American Heart Association's CarePlan Challenge winners showcase AI-powered digital health solutions for cardiovascular care, integrating CarePlans and PREVENT tools to transform patient outcomes.
November 4, 2025 — Maryland faces triple crisis: Chesapeake Bay ecosystem collapse over menhaden, SNAP benefits battle during shutdown, and major energy policy shifts affecting power generation and offshore wind projects.
November 4, 2025 — Pacylex & Heidelberg Pharma reveal zelenirstat as potent ADC payload with 1000x cancer cell potency. New cancer treatment approach shows promise for breast & prostate cancers.
November 3, 2025 — Heidelberg Pharma presents new clinical data for HDP-101 ADC showing promising anti-tumor activity in multiple myeloma patients at World ADC Congress 2025.
November 3, 2025 — American Heart Association launches initiative with Kardigan to boost aortic stenosis clinical trial participation & early diagnosis through 40+ hospitals. Learn about new treatment access.
November 3, 2025 — NanoViricides presents groundbreaking antiviral platform targeting COVID, RSV & influenza. Clinical-stage company developing broad-spectrum nanoviricide drugs to prevent viral escape.
November 3, 2025 — Soligenix strengthens its CTCL Medical Advisory Board to advance HyBryte™ therapy development. Clinical-stage biotech company updates expert team for cutaneous T-cell lymphoma treatment program.
November 3, 2025 — Sapu Nano announces first-in-human trial of Sapu-003, an injectable Everolimus for breast cancer, offering higher bioavailability and efficacy. Key partners include SOCRU and Medicilon.